Get informed when a big investor buys or sells
+ FollowOvervalued by 99.5% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $3.22 Million |
|---|---|
| Enterprise Value | $2.93 Million |
| Earnings per Share | $0 |
| Beta | -0.8 |
| Outstanding Shares | 50,835,341 |
| P/E Ratio | -1.59 |
|---|---|
| PEG | 0.49 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.85 |
| Enterprise Value to EBIT | -1.98 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.26 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spect...